Thyrotropin releasing hormone

Summary Thyrotropin releasing hormone (TRH) acutely stimulates release of thyrotropin (TSH) and prolactin from anterior pituitary cells. A considerable number of studies have been performed with neoplastic and nonneoplastic pituitary cells in culture to elucidate the sequence of intracellular events involved in this action. Although cyclic AMP was suggested as an intracellular messenger, it has been demonstrated that TRH stimulation of hormone release can be dissociated from changes in cyclic AMP concentration, thereby supporting the contention that cyclic AMP is not a required mediator. In contrast, stimulation of hormone release by TRH requires Ca²⁺ and it seems likely that Ca²⁺ is the intracellular coupling factor between TRH stimulation and hormone secretion. TRH has been shown to stimulate ⁴⁵Ca²⁺ efflux from preloaded pituitary cells. Enhanced ⁴⁵Ca²⁺ efflux is thought to reflect an increase in the free intracellular Ca²⁺ concentration which leads to hormone release; however, the source of this Ca^2– is uncertain. Results are reviewed from a series of experiments in pituitary cells which attempt to determine the pool (or pools) of Ca²⁺ that is affected by TRH. These include the following: the effects of decreasing the extracellular Ca^2– concentration on hormone release stimulated by TRH; the effect of TRH on cellular Ca²⁺ as monitored by chlortetracycline; the effects of TRH on Ca²⁺ influx; the effects of the organic Ca²⁺ channel blocking agents, verapamil and methoxyverapamil, on TRH-stimulated hormone release; and the effects of TRH on plasma membrane potential difference and on Ca²⁺-dependent action potentials. Based on these data, separate hypotheses of the early events in TRH stimulation of hormone release in mammotropes and thyrotropes are proposed. In mammotropes, TRH is thought to stimulate prolactin release optimally by elevating the free intracellular Cat+ concentration by mobilizing cellular Ca^2– only. In contrast, in thyrotropes under normal physiological conditions, TRH is thought to stimulate TSH release by mobilizing Ca² from a cellular pool (or pools) and to augment this effect by also inducing influx of extracellular Ca²⁺ through voltage-dependent channels in the plasma membrane.     

Conformational energy studies on N-methylated analogs of thyrotropin releasing hormone, enkephalin, and luteinizing hormone-releasing hormone

Empirical conformational energy calculations have been carried out for N-methyl derivatives of alanine and phenylalanine dipeptide models and N-methyl-substituted active analogs of three biologically active peptides, namely thyrotropin-releasing hormone (TRH), enkephalin (ENK), and luteinizing hormone-releasing hormone (LHRH). The isoenergetic contour maps and the local dipeptide minima obtained, when the peptide bond (ω) preceding the N-methylated residue is in the trans configuration show that (1) N-methylation constricts the conformational freedom of both the ith and (i + 1)th residues; (2), the lowest energy position for both residues occurs around ? = ?135° ± 5° and ψ = 75° ± 5°, and (3) the α_L conformational state is the second lowest energy state for the (i + 1)th residue, whereas for the ith residue the C₅ (extended) conformation is second lowest in energy. When the peptide bond (ω_i) is in the cis configuration the ith residue is energetically forbidden in the range ? = 0° to 180° and ψ = ?180° to +180°. Conformations of low energy for ω_i = 0° are found to be similar to those obtained for the trans peptide bond. In all the model systems (irrespective of cis or trans), the α_R conformational state is energetically very high. Significant deviations from planarity are found for the peptide bond when the amide hydrogen is replaced by a methyl group. Two low-energy conformers are found for [(N-Me)His²]TRH. These conformers differ only in the ? and ψ values at the (N-Me)His² residue. Among the different low-energy conformers found for each of the ENK analogs [D -Ala²,(N-Me)Phe⁴, Met⁵]ENK amide and [D -Ala²,(N-Me)Met⁵]ENK amide, one low-energy conformer was found to be common for both analogs with respect to the side-chain orientations. The stability of the low-energy structures is discussed in the light of the activity of other analogs. Two low-energy conformers were found for [(N-Me)Leu⁷]LHRH. These conformations differ in the types of bend around the positions 6 and 7 of LHRH. One bend type is eliminated when the active analog [D -Ala⁶,(M-Me)Leu⁷]LHRH is considered.     

Minireview. Thyrotropin releasing hormone and CNS cholinergic neurons

The centrally mediated pharmacological effects of thyrotropin releasing hormone (TRH), their mechanistic basis and therapeutic implications, along with the possible physiological significance of extrahypothalamic TRH, have been the subject of numerous investigations for over a decade. Despite this effort a holistic perspective on these issues and considerations does not exist. However, with continued research employing multiple and diverse experimental approaches, many interactions of TRH and related peptides with central cholinergic mechanisms have been revealed. These interactions are documented in this review and it is proposed that they can account for several of the more prominent pharmacological actions of these peptides. Additionally, it is suggested that a function of endogenous YHR, throughout the neuroaxis, may be to regulate the excitability of central cholinergic neurons.     

Thyrotropin releasing hormone: enhancement of DOPA activity in thyroidectomized rats

This study demonstrates that TRH potentiated the behavioral effects of DOPA-pargyline in thyroidectomized rats as well as in normal rats. This behavioral effect of TRH therefore can be considered to be independent of the thyroid gland in the DOPA potentiation test. Possible mechanisms and clinical implications are discussed.     

Estrogen and the subcellular distribution of luteinizing hormone releasing hormone: Rate sedimentation studies

Rate sedimentation of the 900×G supernatants (S₁) of hypothalamic homogenates from untreated male rats or ovariectomized rats with or without 5 μg estradiol benzoate (EB) revealed two populations of LHRH particles: a minor, slowly sedimenting one (peak 1) and a major, more rapidly sedimenting one (peak 2). Some LHRH-containing material also sedimented to the bottom of the gradient. The ovariectomized rats displayed more heterogeneity of particulate LHRH than did the male rats. Furthermore, the administration of EB to ovariectomized rats altered the relative sedimentation pattern of LHRH. In ovariectomized rats, hypotonic shock of S₁ prior to rate sedimentation eliminated peak 2 and post-peak 2 LHRH and increased free LHRH at the top of the gradient. Peak 1 LHRH was still present and was elevated after EB treatment. Also, EB treatment lowered the free LHRH at the top of the gradient. These data demonstrate that the administration of EB to an ovariectomized rat alters the subcellular distribution of LHRH.     

Thyrotropin releasing hormone antagonizes beta endorphin hypothermia and catalepsy.

Injection of 30 μg β endorphin intraventricularly (ivt) in rats produced an alteration of body temperature, a state of catalepsy, and an increase in antinociceptive latencies. Subsequent ivt injections of 20 μg of thyrotropin releasing hormone (TRH) reversed the ongoing changes in body temperature and catalepsy produced by β endorphin. Since TRH antagonized these effects in hypophysectomized rats, it is implied that these effects of TRH are independent of pituitary-thyroid involvement. In contrast to the above, TRH did $\text{not}$ alter the antinociception produced by β endorphin in either sham-control or hypophysectomized rats. The failure of TRH to antagonize all three of these opiate effects, as well as the inability of TRH to displace bound dihydromorphine from synaptic plasma membranes, suggests that the level of TRH-β endorphin interaction is not at the opiate receptor.     

Estrogen and the subcellular distribution of luteinizing hormone releasing hormone: Rate sedimentation studies

Rate sedimentation of the 900×G supernatants (S₁) of hypothalamic homogenates from untreated male rats or ovariectomized rats with or without 5 μg estradiol benzoate (EB) revealed two populations of LHRH particles: a minor, slowly sedimenting one (peak 1) and a major, more rapidly sedimenting one (peak 2). Some LHRH-containing material also sedimented to the bottom of the gradient. The ovariectomized rats displayed more heterogeneity of particulate LHRH than did the male rats. Furthermore, the administration of EB to ovariectomized rats altered the relative sedimentation pattern of LHRH. In ovariectomized rats, hypotonic shock of S₁ prior to rate sedimentation eliminated peak 2 and post-peak 2 LHRH and increased free LHRH at the top of the gradient. Peak 1 LHRH was still present and was elevated after EB treatment. Also, EB treatment lowered the free LHRH at the top of the gradient. These data demonstrate that the administration of EB to an ovariectomized rat alters the subcellular distribution of LHRH.     

Conformational studies on the enkephalin releasing peptides,Tyr-Arg and Tyr-D-Arg

Conformational energy calculations were carried out on the enkephalin releasing peptides, Tyr-Arg and Try-D-Arg. The conformations of low energy were found to result in two configurations in which the side-chains were either on opposite sides of the backbone (R1) or parallel to one another (R2). A comparison of the two molecules suggests that configuration R2 is most probably the active structure. A method for testing this hypothesis is presented.     

Thyrotropin releasing hormone: autonomic effects upon cardiorespiratory function in endotoxic shock

These studies define potential sites and mechanisms by which thyrotropin releasing hormone (TRH) stimulates cardiorespiratory function in normotensive rats as well as in rats subjected to endotoxic shock. Changes in mean arterial pressure, pulse pressure, heart rate, and respiratory rate were determined in conscious animals following injection of TRH into the lateral, third, or fourth ventricular spaces. Injections of TRH into the third ventricular space resulted in a greater increase in cardiorespiratory variables than did fourth ventricular injection. In endotoxin-treated rats, the cardiorespiratory effects of intracerebroventricular (icv) TRH and its analog MK 771 were assessed. TRH and MK 771 were shown to act within the brain to reverse endotoxic shock hypotension; at the doses used, the pressor effects of these two tripeptides were achieved through selectively different actions upon heart rate and pulse pressure. Adrenal demedullated and sham-operated control rats subjected to endotoxic shock were injected with icv and intravenous (iv) TRH in order to evaluate the potential involvement of sympatho-medullary function in cardiorespiratory responses. The cardiovascular effects of icv TRH were dependent upon adrenal medullary integrity; effects of iv TRH were not. Doses of iv TRH which effectively reverse shock neither altered nociceptive latencies nor interfered with analgesic responses to morphine. Collectively, these studies reinforce the potential therapeutic utility of TRH and its analogs in the treatment of shock and indicate potential sites and mechanisms which mediate these salutary effects.     

The localization of oxytocin,vasopressin, somatostatin and luteinizing hormone releasing hormone in the rat neurohypophysis

Summary The hypothalamic hormones arginine-vasopressin (AVP), oxytocin (OXT), somatostatin (SOM), and luteinizing hormone-releasing hormone (LHRH) were localized in the rat neurohypophysis by the use of semithin serial sections and the unlabeled antibody enzyme method. Clusters of AVP fibres are present within the central region of the neural lobe, clusters of OXT fibres mainly in the peripheral part. The AVP fibres enter bilaterally into the neural lobe.The results call into question previous reports on the presence of AVP on receptors in the pars intermedia cells, since incubation with anti-AVP resulted in similar staining in the pars intermedia of the Wistar and homozygous Brattleboro rat, a mutant strain deficient in AVP. The same intermediate lobe cells are stained after incubation of serial sections with anti-AVP and anti--melanocyte-stimulating hormone (-MSH). This staining of anti-AVP could be removed by solid phase absorption to -MSH and is thus most probably due to cross reaction with -MSH. SOM fibres appear to be present in the peripheral parts of the proximal neurohypophysial stalk and mainly lateral in its more distal parts. In the neural lobe they rapidly decrease in number, although some fibres continue into the distal part of the neural lobe, running bilaterally and situated adjacent to the pars intermedia. The SOM staining within magnocellular elements, which has been reported in the literature, can most probably be explained by cross reaction of anti-SOM with neurophysins. LHRH fibres are very scarce in the neurohypophysial stalk and absent in the neural lobe.Supported by the Foundation for Medical Research FUNGOThe authors wish to thank Drs. J. De Mey (Beerse, Belgium), A. Arimura (New Orleans, U.S.A.), M.P. Dubois (Nouzilly, France), B.L. Baker (Ann Arbor, U.S.A.) and A.G.E. Pearse (London, U.K.) for their gifts of anti-somatostatin serum, Dr. B. Kerdelhué (Gif-sur-Yvette, France) for anti-LHRH serum, and Dr. F. Vandesande (Ghent, Belgium) for anti-neurophysin I and II serum and bovine neurophysin I and II. Dr. J.G. Streefkerk (Free University, Amsterdam) is acknowledged for critical comments and Mr. A.T. Potjer and Miss J. van der Velden for their skilled assistance     

Thyrotropin releasing hormone in the pancreas of newborn rats from streptozotocin-treated mothers

The effect of maternal diabetes (induced by i.p. injections of 40-50 mg/kg BW Streptozotocin on the day of mating) on TRH in the pancreas of newborn rats was studied. Determination of peptide alpha amidation activity and TRH precursor level on the day of birth revealed decreased biosynthesis of TRH resulting in profoundly (10 times) lower pancreatic TRH and TRH-OH concentrations in pups of diabetic rats. Pancreatic His-Pro-diketopiperazine (His-Pro-DKP) remained unaffected by maternal diabetes. The depression of pancreatic TRH was less profound 24 h later, and even elevated TRH was measured in the pancreas of pups of diabetic mothers on postnatal day 5. Short term postnatal starvation or nursing of intact pups by the diabetic foster mother did not affect pancreatic TRH. It could be postulated that postnatal TRH development in the rat pancreas is retarded by maternal diabetes, while His-Pro-DKP remains unaltered.     

Thyrotropin releasing hormine (TRH): distribution in the brain, blood and urine of the rat

Measurement of thyrotropin releasing hormone (TRH) in the rat by a radioimmunoassay capable of detecting 6 pg is described. TRH was found in high concentration in the hypothalamus, especially in the stalk median eminence (SME). Small but significant concentrations were also detected hroughout the extrahypothalmic brain. Quantitatively, these levels are substantial, and suggest that this tripeptide may have an extrathyroidal brain function. TRH was measurable in the blood only in low concentrations, but large amounts were excreted in the urine (18.4ng/day).     

Thyrotropin releasing hormone receptors in regulation of prolactin gene expression in GH cells

Calf thymus DNA polymerase β and mammalian type C retroviral DNA polymerases are strongly inhibited by low concentrations (1–2mM) of inorganic phosphate (Pi). A detailed analysis of this phenomenon revealed that Pi-mediated inhibition: a) requires the presence of Mn²⁺ (Mg²⁺ neither supports nor relieves this inhibition; b) is strongly affected by the stoichiometric relationship between Mn²⁺ and Pi concentrations; c) is competitive with respect to deoxynucleoside triphosphate (dNTP) concentration, and d) increasing the concentration of substrate or non-substrate dNTPs in reaction mixtures raised the concentration of Mn²⁺ at which significant inhibition by a fixed concentration of Pi was first seen. These findings suggested that Mn²⁺, dNTPs, and Pi may interact in Pi-mediated inhibition. Thin-layer chromatographic analysis revealed the formation of an Mn-dNTP-Pi complex, while Mg²⁺ did not participate in such complex formation. We propose that it is this tripartite complex which is responsible for the Pi-mediated inhibition of sensitive DNA polymerases.     

Thyrotropin releasing hormone (TRH) binding sites in the adult human brain: localization and characterization

In the current study, we found evidence for the existence of binding sites for TRH in synaptic membrane preparations of several regions of the postmortem adult human brain. High levels of specific binding (fmol [3H]Me-TRH/mg protein/2 hr) were found in limbic structures: amygdala (7.1 +/- 0.6, Mean +/- SE), hippocampus (2.8 +/- 0.3), and temporal cortex (2.4 +/- 0.8). Intermediate levels of binding were found in the hypothalamus and nucleus accumbens whereas binding was low to undetectable in frontal and occipital cortex, cerebellum, pons, medulla and corpus striatum. Binding of the radioligand was linear over protein concentrations of 0.05-1.5 mg, and greater than 6 hr of incubation was required to achieve maximal binding. In the amygdala, binding was inhibited in the presence of TRH and Me-TRH but not in the presence of up to 1 microM concentrations of cyclo (His-Pro), TRH-OH, pGlu-His or peptides unrelated to TRH. Pretreatment of amygdala synaptic membranes with detergents, proteases or phospholipases disrupted [3H]Me-TRH binding; pretreatment with DNase or collagenase had no effect on binding. Saturation and association/dissociation analyses of the binding of [3H]Me-TRH to purified amygdala synaptic membranes revealed the presence of a high affinity (KD = 2.0 nM), low capacity (Bmax = 180 +/- 16 fmoles/mg protein) binding site. These results demonstrate that a highly specific membrane associated receptor for TRH is present in the adult human brain. The specific role that this receptor plays in brain function remains to be elucidated.     

Thyrotropin releasing hormone: direct evidence for stimulation of prolactin production by pituitary cells in culture

Addition of thyrotropin releasing hormone (TRH) to the medium of 2 clonal strains of functional rat pituitary cells stimulated the production of prolactin and inhibited growth hormone production. There was no effect on cell growth. Stimulation of prolactin production by TRH was detected within 4 hr, it reached a maximum level (2–5 times control) at 24–48 hr and persisted for at least 20 days in the continued presence of TRH. Stimulation was observed with a concentration of TRH as low as 0.10 ng/ml.     

Thyrotropin releasing hormone (TRH) selectively binds and activates the melanocortin 1 receptor.

We tested the endogenous tripeptide TRH (thyrotropin releasing hormone) ability to bind to MC (melanocortin) receptor subtypes. We discovered that TRH binds to the human MCI receptor expressed in COS cells and to murine B16 melanoma cells with 5790+/-1010 nM and 6370+/-1260 nM Ki's, respectively. TRH did not bind to the human MC3, MC4 or MC5 receptor subtypes. Moreover, TRH also stimulated cAMP production in murine B16 melanoma cells reaching the same maximum level of cAMP as found for alpha-MSH. However, several analogues of TRH, including TRH-OH, TRH-Gly-NH2 and other analogues, where each of the three amino acid residues in TRH had been exchanged by a related residue, did not bind to any of the MC receptors tested in this study. C(alpha) atoms of molecular models of TRH and the core of a MSH peptide were aligned with r.m.s. of 0.01 A. Moreover, TRH could be docked into a binding pocket of a molecular model of the MC1 receptor at only a little higher energy than a short cyclic MSH peptide. The data indicate a similarity in the mode of TRH and MSH activation of the MCI receptor.     

Gonadotropin releasing hormone (GnRH): Neuropharmacological studies

The hypothalamic hormone GnRH was found to potentiate behavioral effects of DOPA and serotonin. In addition, GnRH was observed to reduce slightly audiogenic seizures as well as spontaneous motor activity. No significant effects were observed against footshock induced fighting or oxotremorine effects. These studies support our concept of the actions of hypothalamic peptides on the central nervous system.